L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000681:Amylases / Q000097:blood; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001806:Blood Urea Nitrogen; D001927:Brain Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D002784:Cholesterol / Q000097:blood; D004342:Drug Hypersensitivity / Q000209:etiology; D004926:Escherichia coli / Q000201:enzymology; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010195:Pancreatitis / Q000139:chemically induced; D012709:Serum Albumin / Q000032:analysis; D014511:Uremia / Q000139:chemically induced
D012709:Serum Albumin; D002784:Cholesterol; D000469:Alkaline Phosphatase; D000681:Amylases; D001215:Asparaginase; D001663:Bilirubin